Work

BRD4 inhibition for the treatment of pathological organ fibrosis

Year: 2017
Type: review
Abstract: Fibrosis is defined as excess deposition of extracellular matrix, resulting in tissue scarring and organ dysfunction. It is estimated that 45% of deaths in the developed world are due to fibrosis-induced organ failure. Despite the well-accepted role of fibrosis in the pathogenesis of numerous diseases, there are only two US Food and Drug Administration-approved anti-fibrotic therapies, both of which are currently restricted to the treatment of pulmonary fibrosis. Thus, organ fibrosis represents a massive unmet medical need. Here, we review recent findings suggesting that an epigenetic regulatory protein, BRD4, is a nodal effector of organ fibrosis, and we highlight the potential of small-molecule BRD4 inhibitors for the treatment of diverse fibrotic diseases.
Language: English
Open Access status: gold
Estimated APC paid: $1,350
OpenAlex ID: W2727043747
FWCI: 0.544
Cites: 44
Cited by: 60
Related to: 10